FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca's Fasenra ...

AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

Image Source: Zacks Investment Research The FDA nod for Fasenra in EGPA was based on data from the phase III MANDARA study. The MANDARA head-to-head study compared a single monthly injection of ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

Under Colorado’s affordability program any time an eligible uninsured Coloradan acquires an auto-injector from a pharmacy in ...

Amneal Pharmaceuticals has sued Colorado in an effort to block a state law requiring it to provide free generic EpiPens to ...

Patients were randomised to receive either a single 30 mg subcutaneous injection of Fasenra, or three separate 100 mg subcutaneous injections of mepolizumab every four weeks. In the trial, nearly 60% ...